News Percheron Therapeutics Limited Deutsche Boerse AG

Equities

AWY0

AU0000317281

Delayed Deutsche Boerse AG Other stock markets 02:28:45 2024-07-17 am EDT			5-day change	1st Jan Change
0.0438 ^EUR	-3.10%		-4.99%	+42.21%

Jun. 17	Percheron Therapeutics Appoints CFO	MT
Jun. 03	Percheron Therapeutics Names Chief Medical Advisor	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Percheron Therapeutics Appoints CFO	Jun. 16	MT
Percheron Therapeutics Names Chief Medical Advisor	Jun. 02	MT
Percheron Therapeutics Completes Enrollment for Phase Two Muscular Dystrophy Trial; Shares Rise 3%	May. 28	MT
Percheron Therapeutics Secures US Patent for Muscular Dystrophy Medicinal Candidate	May. 19	MT
WHO Selects International Nonproprietary Name for Percheron Therapeutics' Drug Candidate ATL1102	May. 05	MT
Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Dimerix Appoints Nonexecutive Chair	Nov. 19	MT
Antisense Therapeutics Limited has Changed its Name to Percheron Therapeutics Limited	Nov. 15	CI
Antisense Therapeutics Launches Share Sale Facility for Unmarketable Parcels	23-10-09	MT
Antisense Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Antisense Therapeutics' Share Purchase Plan Raises AU$3.3 Million	23-08-21	MT
Antisense Therapeutics Appoints CEO/Managing Director	23-08-06	MT
Antisense Therapeutics Limited Announces Commencement of James Garner as Chief Executive Officer, Effective 7 August 2023	23-08-06	CI
Antisense Therapeutics Limited Announces Management Changes	23-08-06	CI
Antisense Therapeutics to Launch Share Purchase Plan; Shares Plunge 8%	23-07-20	MT
Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK	23-06-27	CI
Antisense Therapeutics Doses First Patient in Duchenne Muscular Dystrophy Drug Trial; Shares Jump 11%	23-06-07	MT
Antisense Therapeutics Appoints CEO/Managing Director	23-05-08	MT
Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023	23-05-07	CI
Antisense Therapeutics Limited Appoints James Garner as Managing Director and to Join the Board as a Non-Executive Director	23-05-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Percheron Therapeutics Limited Deutsche Boerse AG

Equities

AWY0

AU0000317281

Summary

Filters